SCHEMBL3423364

SCHEMBL3423364

COC(=O)CC(C)CNC(=O)OC(C)(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.43
MEN1 O00255 1/20 0.42
GAA P10253 1/20 0.42
KMT2A Q03164 1/20 0.42
CA2 P00918 2/20 0.41
CA12 O43570 2/20 0.41
CA14 Q9ULX7 2/20 0.41
PCSK9 Q8NBP7 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
CA1 P00915 1/20 0.40
CA7 P43166 1/20 0.40
CTSK P43235 5/20 0.39
CTSS P25774 2/20 0.39
CTSL P07711 1/20 0.39
CTSB P07858 1/20 0.39
SYK P43405 1/20 0.37
SERPINE1 P05121 1/20 0.37
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36
AAK1 Q2M2I8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1105702 0.85 PCSK9 (0.50) CYP2D6MEN1GAAKMT2ACA2
SCHEMBL21452654 0.84 MEN1 (0.44) CYP2D6MEN1GAAKMT2ACA2
SCHEMBL4740871 0.84 MEN1 (0.47) CYP2D6MEN1GAAKMT2ACA2
SCHEMBL21452652 0.84 MEN1 (0.44) CYP2D6MEN1GAAKMT2ACA2
SCHEMBL6945578 0.84 MEN1 (0.47) CYP2D6MEN1GAAKMT2ACA2
SCHEMBL1262597 0.84 MEN1 (0.47) CYP2D6MEN1GAAKMT2ACA2
SCHEMBL4961848 0.84 SYK (0.40) CYP2D6MEN1GAAKMT2ACA2
SCHEMBL3421169 0.83 MEN1 (0.44) CYP2D6MEN1GAAKMT2ACA2
SCHEMBL1261059 0.83 MEN1 (0.51) CYP2D6MEN1GAAKMT2ACA2
SCHEMBL22730807 0.83 MEN1 (0.41) CYP2D6MEN1GAAKMT2ACA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9399639-B2 Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use CALITOR SCIENCES, LLC (US) 2016-07-26 US disclosed
US-20140056849-A1 SUBSTITUTED AZAINDOLE COMPOUNDS, SALTS, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS OF USE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2014-02-27 US disclosed
CN-102015699-A Heterocyclic urea derivatives and methods of use thereof-211 ASTRAZENECA AB 2011-04-13 CN disclosed
WO-2010065709-A2 HYDROXAMIC ACID DERIVATIVES, PREPARATION AND THERAPEUTIC USES THEREOF KHAN AMIN (US) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140056849-A1 SUBSTITUTED AZAINDOLE COMPOUNDS, SALTS, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS OF USE TPMT, CYP3A5, AZI2 CYP2D6 8/4885MEN1 351/4885GAA 669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.